These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 33708847)

  • 1. DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
    Rong G; Yi Z; Ma F; Guan Y; Xu Y; Li L; Xu B
    Ann Transl Med; 2021 Feb; 9(3):220. PubMed ID: 33708847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
    Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
    Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
    Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
    EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival Outcomes by
    Meric-Bernstam F; Zheng X; Shariati M; Damodaran S; Wathoo C; Brusco L; Demirhan ME; Tapia C; Eterovic AK; Basho RK; Ueno NT; Janku F; Sahin A; Rodon J; Broaddus R; Kim TB; Mendelsohn J; Mills Shaw KR; Tripathy D; Mills GB; Chen K
    JCO Precis Oncol; 2018; 2018():. PubMed ID: 30035249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
    Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
    PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
    Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
    JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiles and circulating tumor-DNA detected in Chinese early stage breast cancer.
    Lan J; Zhou YH; Zhang MX; Chen DQ; Wu MY; Yu ZY
    Gland Surg; 2022 Feb; 11(2):319-329. PubMed ID: 35284312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
    Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
    J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
    Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
    Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.
    Yi Z; Ma F; Rong G; Guan Y; Li C; Xu B
    Cancer Commun (Lond); 2020 Jun; 40(6):260-269. PubMed ID: 32436611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
    Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients.
    Muendlein A; Geiger K; Gaenger S; Dechow T; Nonnenbroich C; Leiherer A; Drexel H; Gaumann A; Jagla W; Winder T; Mayer F; Decker T
    Sci Rep; 2021 Mar; 11(1):6761. PubMed ID: 33762647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer.
    R HC; Kumar S U; R G; Naayanan PJ; Sathiyarajeswaren P; Devi MSS; K SS; Doss C GP
    J Cell Biochem; 2023 Feb; 124(2):188-204. PubMed ID: 36563059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
    Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
    Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
    Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.